Senores Pharmaceuticals Limited has submitted a regulatory disclosure to both BSE Limited and National Stock Exchange of India Limited regarding scheduled analyst and institutional investor meetings. The filing is made pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
The meetings are scheduled for September 2, 2026, starting at 11:00 AM IST and continuing onwards. The meetings will be hosted by Elara Capital and will include both group meetings and one-on-one sessions. All meetings will be conducted physically in Mumbai.
The company explicitly states that discussions during these interactions will be based solely on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during these meetings.
The disclosure notes that changes to the schedule may occur due to exigencies on the part of either the host (Elara Capital) or the company itself.
The document is digitally signed by Shilpa Sharma, Company Secretary & Compliance Officer (Membership No.: A34516) on August 27, 2026, at 12:25:36 IST. Company contact information is provided: 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India, with phone +91 79 2999 9857, email info@senorespharma.com, and website www.senorespharma.com. The company's CIN is L24290GJ2017PLC100263.